Patents by Inventor Indranil Nandi
Indranil Nandi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240074721Abstract: The present invention provides an image processing method to assess quantitative myocardial blood flow and/or myocardial flow reserve, comprising the steps of: (a) pre-processing of images comprises: (i) reconstructing dynamic cine 3D tomographic myocardial perfusion imaging (MPI) data, (ii) optionally, denoising to improve the quality of image, (iii) extracting blood input function from a region of interest (ROI) of the left ventricle blood cavity, (iv) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K1/k2) to stabilize and improve estimation of K1, k2 and total blood volume (TBV) and subsequent myocardial blood flow measures, and (v) data normalization by dividing by the maximum of the blood input function; (b) assessing the individual signals pre-processed in step (a) in order to generate K1 and TBV parametric maps using artificial neural network; (c) post-processing of K1, k2 and TBV parametric maps; and of rest and stress myocardial blood flow to estimate myocaType: ApplicationFiled: September 5, 2023Publication date: March 7, 2024Inventors: Eric James Moulton, Robert A. DeKemp, Indranil Nandi, Chad Roger Ronald Nicholas Hunter
-
Publication number: 20240047090Abstract: The present invention relates to a medical radioisotope transport system that securely holds the radiopharmaceutical imaging system or medical elution system to the floor of a vehicle and ensures the protection of the elution system during transportation. The transport system as per the present invention includes at least a floor-mounting device, a support mechanism with transportation plates, and a locking device. The transport system as per the present invention is encompassed with advanced technical and safety features to ensure safe transportation of radiopharmaceuticals ensuring compliance to the regulatory and quality requirements. The transport system as per the present invention is easy to use, and successfully overcome all the complexities involved in prior available methods for transportation of radiopharmaceutical imaging systems or medical radioisotope elution systems.Type: ApplicationFiled: June 12, 2023Publication date: February 8, 2024Applicant: Jubilant Draximage Inc.Inventors: Tanima Ghosh, Chadi Baida, Michael Gertsenchtein, Steve Mupenda, Indranil Nandi
-
Publication number: 20240010675Abstract: Disclosed herein is a process for preparing a highly concentrated allergenic intermediate from a dilute allergen extract. This process involves providing a crude extract comprising biological material from an allergenic source, where the biological material comprises a solid phase portion and a liquid phase portion; concentrating the crude extract using pervaporation; adjusting the pH of the concentrated crude extract to 4.0-5.0; treating the concentrated extract with a ketonic solvent to form a precipitate; and recovering the precipitate by filtration to obtain a highly concentrated allergenic intermediate.Type: ApplicationFiled: November 11, 2021Publication date: January 11, 2024Applicant: Jubilant HollisterStier LLCInventors: Derek Constable, Shannon Brown, Indranil Nandi
-
Patent number: 11642351Abstract: The present invention relates to orally administered liquid pharmaceutical compositions of eslicarbazepine. The liquid compositions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile and pH. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide physician with providing a more convenient and less cumbersome posology.Type: GrantFiled: March 23, 2020Date of Patent: May 9, 2023Inventors: Dinesh Kumar, Saurabh Srivastava, Indranil Nandi, Rakesh K. Singh, Amit Jha, Kamal S. Mehta
-
Publication number: 20230110526Abstract: Present invention relates to safety features for radiopharmaceutical dispensing system, wherein dispensing system comprises a controller, a source of radiopharmaceutical and other components. The controller is configured to perform automated quality control of the system to ensure that the system complies quality control before radioactive dose dispensing. The quality control comprises scanning the dispensing system, network or connected devices for an unauthorized connection, malware and ensure that system is free of any such cybersecurity threat before dispensing a radioactive dose.Type: ApplicationFiled: March 25, 2021Publication date: April 13, 2023Applicant: Jubilant Pharma Holdings Inc.Inventor: Indranil Nandi
-
Publication number: 20230093338Abstract: Provided herein are the safety features for radiopharmaceutical infusion system for treatment or diagnostic purpose, wherein infusion system comprises a controller, a source of radiopharmaceutical including other components. The controller is configured to perform automated quality control steps at the start of the system during daily quality control and ensure that system complies to desired technical attributes prior to administration to patients. The quality control steps comprise calibration, breakthrough testing, checking for unauthorized connection and/or malware in the system, network or other connected devices.Type: ApplicationFiled: February 26, 2021Publication date: March 23, 2023Applicant: Jubilant Pharma Holdings Inc.Inventor: Indranil Nandi
-
Publication number: 20230084536Abstract: The present invention relates to a pharmaceutical cold kit composition comprising a chelating agent linked to somatostatin receptor binding organic moiety, a stabilizer, a buffer, and a caking agent or bulking agent, wherein the composition is free of sequestering agent. Further, the present invention also relates to the process of preparing reconstituted or radiolabeled solution composition having high in use stability and radiochemical purity and use thereof for diagnostic and/or therapeutic purposes.Type: ApplicationFiled: September 12, 2022Publication date: March 16, 2023Applicant: Jubilant RadiopharmaInventors: Vijayaraj Kuniyil Kulangara, Riadh Zriba, Tusharmouli Mukherjee, Indranil Nandi, Miriam Ruiz Pena
-
Patent number: 11583521Abstract: Provided herein are the long-acting injection compositions of ?3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using these dosage forms for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical attributes.Type: GrantFiled: June 30, 2021Date of Patent: February 21, 2023Assignee: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Tusharmouli Mukherjee
-
Publication number: 20230046186Abstract: The present invention relates to a process for the preparation of angiotensin receptor blockers or its pharmaceutically acceptable salts thereof containing less than 10 ppm of the azido impurities.Type: ApplicationFiled: May 9, 2022Publication date: February 16, 2023Applicant: Jubilant Pharma Holdings Inc.Inventors: Saji Thomas, Rajendra Shekhawat, M. Umamaheshwar Prasad, Bidyut Biswas, Rohit Chakravarthy, Chetan Balubhai Patel, Anilkumar Haribhat Lingabhat, Mohan Chikmagalur Sadashivappa, Indranil Nandi
-
Publication number: 20230012402Abstract: Provided herein are the long-acting injection compositions of ?3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using the prepared dosage forms for the removal of undesirable body fat for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical and clinical attributes.Type: ApplicationFiled: September 8, 2022Publication date: January 12, 2023Applicant: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Nagabasayya R. Chikkamath, Dinesh Kumar, Tusharmouli Mukherjee
-
Publication number: 20230000837Abstract: Disclosed are the injection compositions of ?3 adrenoreceptor agonists such as mirabegron or their pharmaceutically acceptable salts or solvates or esters thereof. The present invention also relates to methods for preparing injection compositions and methods of using these dosage forms for the treatment of obesity, other related metabolic diseases, and reduction/removal of fat. The injection compositions as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating. The compositions can also be used in cases where oral administration of the drug is not possible due to underlying conditions or concerns around inadequate oral absorption. The injection compositions as per the present invention have desirable pharmaceutical technical attributes.Type: ApplicationFiled: April 20, 2022Publication date: January 5, 2023Applicant: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Tusharmouli Mukherjee, Nagabasayya R. Chikkamath
-
Publication number: 20220370477Abstract: The present invention relates to solid oral pharmaceutical compositions comprising dexamethasone or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing solid oral pharmaceutical compositions comprising dexamethasone or its pharmaceutically acceptable salts or solvates thereof. The preferred drug load in the compositions of the present invention is from about 0.01% to 15% by weight based on the total weight of the composition. The prepared compositions of dexamethasone as per the present invention exhibit desirable technical attributes.Type: ApplicationFiled: May 12, 2022Publication date: November 24, 2022Applicant: Jubilant Generics LimitedInventors: Mitesh Nagar, Nilesh Jaiswal, Indranil Nandi, Sunil Yadav, Dinesh Kumar
-
Publication number: 20220273670Abstract: The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.Type: ApplicationFiled: May 17, 2022Publication date: September 1, 2022Applicant: Jubilant Generics LimitedInventors: Dinesh Kumar, Indranil Nandi, Rakesh K. Singh
-
Publication number: 20220265552Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology. The suspension compositions as per present invention are useful for the treatment of seizures, partial-onset seizures, epilepsy, neuropathic pain, migraine, fibromyalgia, trigeminal neuralgia, bipolar disorders, attention disorders, anxiety disorders, affective disorders, schizoaffective disorders, sensorimotor disorders, and vestibular disorders.Type: ApplicationFiled: May 2, 2022Publication date: August 25, 2022Applicant: Jubilant Generics LimitedInventors: Indranil Nandi, Dinesh Kumar, Rakesh Singh, TUSHARMOULI MUKHERJEE
-
Publication number: 20220202698Abstract: Provided herein are the extended release pharmaceutical composition suitable for once or twice daily dosing comprising riociguat and at least one or more pharmaceutically acceptable excipients. The present invention also relates to method for preparing extended release composition and method of using these dosage forms for the treatment of pulmonary hypertension and related diseases. The present invention provides extended release composition of riociguat which are expected to exhibit desired technical attributes such as assay, stability and release profile suitable for once or twice daily administration.Type: ApplicationFiled: December 27, 2021Publication date: June 30, 2022Applicant: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Rakesh Kumar Singh
-
Patent number: 11331324Abstract: The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.Type: GrantFiled: March 24, 2020Date of Patent: May 17, 2022Inventors: Dinesh Kumar, Saurabh Srivastava, Indranil Nandi, Rakesh K. Singh, Amit Jha, Kamal S. Mehta
-
Patent number: 11327065Abstract: The present invention relates to a process for the preparation of angiotensin receptor blockers or its pharmaceutically acceptable salts thereof containing less than 10 ppm of the azido impurities.Type: GrantFiled: August 27, 2021Date of Patent: May 10, 2022Inventors: Saji Thomas, Rajendra Shekhawat, M. Umamaheshwar Prasad, Bidyut Biswas, Rohit Chakravarthy, Chetan Balubhai Patel, Anilkumar Haribhat Lingabhat, Mohan Chikmagalur Sadashivappa, Indranil Nandi
-
Patent number: 11318145Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.Type: GrantFiled: May 21, 2021Date of Patent: May 3, 2022Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Rakesh K. Singh, Saurabh Srivastava
-
Patent number: 11311518Abstract: Disclosed are the injection compositions of ?3 adrenoreceptor agonists such as mirabegron or their pharmaceutically acceptable salts or solvates or esters thereof. The present invention also relates to methods for preparing injection compositions and methods of using these dosage forms for the treatment of obesity, other related metabolic diseases, and reduction/removal of fat. The injection compositions as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating. The compositions can also be used in cases where oral administration of the drug is not possible due to underlying conditions or concerns around inadequate oral absorption. The injection compositions as per the present invention have desirable pharmaceutical technical attributes.Type: GrantFiled: August 6, 2021Date of Patent: April 26, 2022Assignee: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Tusharmouli Mukherjee, Nagabasayya R Chikkamath
-
Publication number: 20220062213Abstract: Provided herein are compositions and methods useful in the non-surgical removal of fat deposits in patients in need thereof using ?3-adrenoreceptor agonists. The invention further provides a method of treating double chin disorder, benign symmetric lipomatosis, adiposis dolorosa, lipedema, and familial partial lipodystrophy in patients in need thereof by administration of solabegron or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers, or mixtures thereof. The treatment method as per the present invention comprises treatment with solabegron or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers, or mixtures thereof suitable for injection administration. The compositions and treatment method as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating without requiring any surgical procedure.Type: ApplicationFiled: September 1, 2021Publication date: March 3, 2022Applicant: Jubilant Pharma Holdings Inc.Inventor: Indranil Nandi